ReviewFrontiers in microbiology2015
Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases.
Review in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis.PLoS pathogens · 2025Article
- Novel Strategies for Preventing Fungal Infections-Outline.Pathogens (Basel, Switzerland) · 2025Review
- Trim72 is a major host factor protecting against lethal Candida albicans infection.PLoS pathogens · 2024Article
- The protein segregase VCP/p97 promotes host antifungal defense via regulation of SYK activation.PLoS pathogens · 2024Article
- The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective.Open forum infectious diseases · 2024Review
- Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.The Journal of antimicrobial chemotherapy · 2023Article
- Ethnobotanical study of medicinal plants utilized in the management of candidiasis in Northern Uganda.Tropical medicine and health · 2022Article
- Essential Oils in Respiratory Mycosis: A Review.Molecules (Basel, Switzerland) · 2022Review
- Article
- TRIM31 facilitates K27-linked polyubiquitination of SYK to regulate antifungal immunity.Signal transduction and targeted therapy · 2021Article
- MYO1F regulates antifungal immunity by regulating acetylation of microtubules.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Interactions of thymic stromal lymphopoietin with interleukin-4 in adaptive immunity duringInternational journal of ophthalmology · 2021Article
- Using Expanded Natural Killer Cells as Therapy for Invasive Aspergillosis.Journal of fungi (Basel, Switzerland) · 2020Article
- Dok3-protein phosphatase 1 interaction attenuates Card9 signaling and neutrophil-dependent antifungal immunity.The Journal of clinical investigation · 2019Article
- Thioredoxin Reductase 1 Is a Highly Immunogenic Cell Surface Antigen inFrontiers in microbiology · 2019Article
- Bifunctional Small Molecules Enhance Neutrophil Activities AgainstFrontiers in immunology · 2019Article
- Invasive fungal infections in high-risk patients: report from TIMM-8 2017.Future science OA · 2018Article
- Immunomodulation as Therapy for Fungal Infection: Are We Closer?Frontiers in microbiology · 2018Review
- Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils.Blood · 2017Article
- Modulating Host Signaling Pathways to Promote Resistance to Infection byFrontiers in cellular and infection microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major global concern is the emergence and spread of systemic life-threatening fungal infections in critically ill patients. The increase in invasive fungal infections, caused most commonly by Candida and Aspergillus species, occurs in patients with impaired defenses due to a number of reasons such as underlying disease, the use of chemotherapeutic and immunosuppressive agents, broad-spectrum antibiotics, prosthetic devices and grafts, burns, neutropenia and HIV infection. The high morbidity and mortality associated with these infections is compounded by the limited therapeutic options and the emergence of drug resistant fungi. Hence, creative approaches to bridge the significant gap in antifungal drug development needs to be explored. Here, we review the potential anti-fungal targets for patient-centered therapies and immune-enhancing strategies for the prevention and treatment of invasive fungal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.